Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications.
about
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implicationsThe experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine useForces influencing generic drug development in the United States: a narrative reviewSources of European drug consumption data at a country level.Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy.Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.Different initiatives across Europe to enhance losartan utilization post generics: impact and implications.Pharmaceutical policies in European countries in response to the global financial crisis.Proton pump inhibitors: potential cost reductions by applying prescribing guidelines.A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.Personalizing health care: feasibility and future implications.Prescribing efficiency of proton pump inhibitors in China: influence and future directionsPolicies to enhance prescribing efficiency in europe: findings and future implications.Influence of Retirement on Adherence to Statins in the Insurance Medicine All-Sweden Total Population Data Base.The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimentaDo newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications.Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.Assessment of antibiotic prescribing at different hospitals and primary health care facilitiesIntroduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureKnowledge and attitudes of the pharmacists, prescribers and patients towards generic drug use in Istanbul - Turkey.Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.What do prescribers think of biosimilars?Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.Demand-side policies to encourage the use of generic medicines: an overview.The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?The influence of hospital drug formulary policies on the prescribing patterns of proton pump inhibitors in primary care.Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.Societal value of generic medicines beyond cost-saving through reduced prices.Physicians' knowledge, perceptions and behaviour towards antibiotic prescribing: a systematic review of the literature.Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa.Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage.High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines.Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction.
P2860
Q21129272-EC9AA733-C07F-494E-B145-ED6FC630253EQ27007695-E8E88553-7D4E-4233-B35A-0630D78B350FQ28070306-F6A961CD-8DED-4689-999E-47989325EA41Q30827537-EEF803E3-85EC-4F23-A6AE-FAD2D67B92B5Q30978981-1DF7444C-7339-44DE-8D41-992524566A4DQ33730376-F55C46BD-E035-4ED8-BAF0-3C5AAB98B1F2Q34304782-1A1F27C3-6518-4E6A-813C-B9E844177D7FQ34307945-CA44ED36-DC0C-46C1-A4B8-653E26D6331FQ34481174-49F8C997-B1C1-4E2A-9664-46A669DC2409Q34536861-C630336C-32E7-4F55-97D6-6530D766E19BQ34938911-E2AD533A-5145-4ECE-8D26-B4FA7B27E72CQ35021173-0AA34E09-CAAB-4D3A-BA3C-D37CBA24269DQ35155250-F3AC6F63-EC73-43F4-939F-5F86E6E948CAQ35671834-44F82623-F1AA-4546-BF73-9CF06407A811Q35770269-E1689EDE-F4DE-4FB8-A83F-66C8E9C796A3Q35990559-63978CC6-8218-4AD7-9E48-F0E44DDA9029Q36512458-18C2D81A-D2ED-4258-B80C-31327079E588Q36841028-FCD111B4-9DD8-4EB1-AE61-DE7D5A473825Q37098928-F17B8349-4C2C-407D-9927-1693F2CB7D94Q37135584-44517A8D-26CD-4FD5-948E-008DC67B19E2Q37190923-AA8511B0-2E5A-4726-9109-AD772845F5F8Q37847158-CBC695FF-FBC4-4B8F-8E70-B8C1067BC6A8Q37977012-A6B1A372-6220-4C6B-96D8-55326101E2F5Q38067640-4FC598FF-DF61-42FD-9A50-21DC7549688DQ38080914-638903D1-219A-4DEB-B6C5-8C8C5950B88BQ38080920-52B496AE-751C-4DFD-85B3-C59442EA992BQ38131544-1CAFA2A8-367F-4658-9B5B-A20387D22567Q38150706-484F2A24-99E5-4B07-9041-42AC97027664Q38162866-08423D78-6D9C-46D8-BB05-63951F39781BQ38162867-3F0024E2-2E64-45EE-AF56-84CD3D9A552FQ38207512-6CFBA410-1487-4287-AB21-E24307AE666FQ38263092-6EE14C84-36E7-42C1-B2BE-9707DE229841Q38361389-29491FCA-F16A-4410-9863-43CBBEA0FA65Q38392582-D295F246-56DA-446B-ADA9-15715A7277BCQ38517704-14F001C7-BC4E-4E84-BB0F-0460F9146372Q38647745-3E8704AF-2F32-453C-94BB-E68D4E978599Q38655036-B3459E45-7EC1-4B89-8193-504A8BCBC5C2Q38808074-B5DDB9C5-F04C-48A2-A1C8-0093D6087B59Q39109315-84FD5A80-B660-43BE-AD50-767E2B14CBADQ39120116-4D5B7A95-1135-4A63-A1E2-DD3D31E7DC9B
P2860
Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Comparing policies to enhance ...... seen and global implications.
@en
Comparing policies to enhance ...... seen and global implications.
@nl
type
label
Comparing policies to enhance ...... seen and global implications.
@en
Comparing policies to enhance ...... seen and global implications.
@nl
prefLabel
Comparing policies to enhance ...... seen and global implications.
@en
Comparing policies to enhance ...... seen and global implications.
@nl
P2093
P356
P1476
Comparing policies to enhance ...... seen and global implications.
@en
P2093
Björn Wettermark
Brian Godman
Catherine Sermet
Christian Berg
Corinne Zara
Diane McGinn
F Cankat Tulunay
Harald Herholz
Iain Bishop
Inês Teixeira
P304
P356
10.1586/ERP.10.72
P577
2010-12-01T00:00:00Z